Allspring Global Investments Holdings LLC Acquires 8,537 Shares of argenex SE $ARGX

Allspring Global Investments Holdings LLC raised its holdings in shares of argenex SE (NASDAQ:ARGX) by 4.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 184,987 shares of the company’s stock after purchasing an additional 8,537 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.30% of argenex worth $100,350,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ARGX. Vanguard Personalized Indexing Management LLC boosted its holdings in argenex by 6.9% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 3,009 shares of the company’s stock worth $1,659,000 after acquiring an additional 195 shares during the last quarter. Sivik Global Healthcare LLC purchased a new position in shares of argenex in the 2nd quarter worth about $1,378,000. Aberdeen Group plc lifted its holdings in argenex by 28.8% during the second quarter. Aberdeen Group plc now owns 70,293 shares of the company’s stock valued at $38,747,000 after purchasing an additional 15,703 shares during the last quarter. IFP Advisors Inc lifted its holdings in argenex by 4.2% during the second quarter. IFP Advisors Inc now owns 666 shares of the company’s stock valued at $367,000 after purchasing an additional 27 shares during the last quarter. Finally, Callan Family Office LLC lifted its holdings in argenex by 301.1% during the second quarter. Callan Family Office LLC now owns 1,452 shares of the company’s stock valued at $800,000 after purchasing an additional 1,090 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenex Trading Up 0.3%

Shares of argenex stock opened at $799.56 on Tuesday. argenex SE has a 12-month low of $510.05 and a 12-month high of $810.16. The company has a market cap of $48.93 billion, a price-to-earnings ratio of 41.00, a PEG ratio of 0.86 and a beta of 0.46. The company’s 50-day moving average price is $722.14 and its 200-day moving average price is $629.47.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, July 31st. The company reported $3.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $0.90. The firm had revenue of $866.79 million for the quarter, compared to the consensus estimate of $776.82 million. argenex had a net margin of 40.98% and a return on equity of 21.06%. On average, sell-side analysts predict that argenex SE will post 3.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

ARGX has been the topic of several recent research reports. JPMorgan Chase & Co. upped their price objective on shares of argenex from $775.00 to $830.00 and gave the company an “overweight” rating in a report on Monday, August 4th. Zacks Research raised shares of argenex from a “hold” rating to a “strong-buy” rating in a report on Monday, September 22nd. Truist Financial upped their price objective on shares of argenex from $700.00 to $918.00 and gave the company a “buy” rating in a report on Monday, September 15th. Piper Sandler upped their price objective on shares of argenex from $750.00 to $820.00 and gave the company an “overweight” rating in a report on Tuesday, August 26th. Finally, Stifel Nicolaus set a $882.00 price objective on shares of argenex in a report on Thursday, September 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $817.53.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.